Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Cholesterol-Lowering pill shows promise in Mid-Stage trial

NCT ID NCT06173570

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new daily medication called AZD0780 in 428 adults with dyslipidemia (abnormal cholesterol levels). Participants took one of several doses of AZD0780 or a placebo for 12 weeks. The main goal was to see how much the drug lowered LDL (bad) cholesterol compared to placebo. The trial also checked safety and how the drug levels changed in the blood. Results showed that AZD0780 effectively reduced LDL cholesterol in a dose-dependent manner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

428 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males, and females of non-childbearing potential 18 to 75 years of age, inclusive, at the time of signing the informed consent. * Participants with a fasting low-density lipoprotein cholesterol (LDL-C) higher than or equal to 70 mg/dL (1.8 mmol/L) and lower than 190 mg/dL (4.9 mmol/L) at screening. * Participants with fasting triglycerides lower than 400 mg/dL (lower than 4.52 mmol/L) at screening. * Should be receiving moderate or high-intensity statin therapy for more than or equal to 2 months prior to screening. * There should be no planned medication or dose change during study participation. * Body mass index at or above 19.0 kg/m\^2. Exclusion Criteria: * History or presence of gastrointestinal, hepatic or renal disease or any other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Any uncontrolled or serious disease, or any medical (e.g., known major active infection or major hematological, renal, metabolic, gastrointestinal, respiratory, or endocrine dysfunction) or surgical condition that, in the opinion of the investigator, may either interfere with participation in the clinical study and/or put the participant at significant risk. * Poorly controlled type 2 diabetes mellitus, defined as hemoglobin A1c (HbA1c) greater than 10 percent at screening. * Acute ischemic cardiovascular event in the last 12 months. * Heart failure with New York Heart Association (NYHA) Class III-IV. * Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years. * Recipient of any major organ transplant, e.g., lung, liver, heart, bone marrow, renal. * LDL or plasma apheresis within 12 months prior to randomization. * Uncontrolled hypertension. * Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG as judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia

Contacts and locations

Locations

  • Research Site

    Huntsville, Alabama, 35801, United States

  • Research Site

    Lincoln, California, 95648, United States

  • Research Site

    Palm Springs, California, 92262, United States

  • Research Site

    Santa Ana, California, 92704, United States

  • Research Site

    Boca Raton, Florida, 33434, United States

  • Research Site

    Hialeah, Florida, 33012, United States

  • Research Site

    Inverness, Florida, 34452, United States

  • Research Site

    Jacksonville, Florida, 32216, United States

  • Research Site

    Indianapolis, Indiana, 46260, United States

  • Research Site

    Louisville, Kentucky, 40213, United States

  • Research Site

    New Windsor, New York, 12553, United States

  • Research Site

    Greensboro, North Carolina, 27408, United States

  • Research Site

    Fargo, North Dakota, 58104, United States

  • Research Site

    San Marcos, Texas, 78666, United States

  • Research Site

    Barrie, Ontario, L4N 7L3, Canada

  • Research Site

    Brampton, Ontario, L6S 0C6, Canada

  • Research Site

    Cambridge, Ontario, N1R 6V6, Canada

  • Research Site

    Concord, Ontario, L4K 4M2, Canada

  • Research Site

    Guelph, Ontario, N1H 1B1, Canada

  • Research Site

    Toronto, Ontario, M6G 1M2, Canada

  • Research Site

    Benešov, 256 01, Czechia

  • Research Site

    Brandýs nad Labem, 250 01, Czechia

  • Research Site

    Brno, 603 00, Czechia

  • Research Site

    Louny, 440 01, Czechia

  • Research Site

    Náchod, 547 01, Czechia

  • Research Site

    Prague, 150 00, Czechia

  • Research Site

    Příbram, 261 01, Czechia

  • Research Site

    Teplice, 415 01, Czechia

  • Research Site

    Uherské Hradiště, 68601, Czechia

  • Research Site

    Aarhus, 8200, Denmark

  • Research Site

    Herning, 7400, Denmark

  • Research Site

    Hvidovre, 2650, Denmark

  • Research Site

    Svendborg, 5700, Denmark

  • Research Site

    Viborg, 8800, Denmark

  • Research Site

    Budapest, 1027, Hungary

  • Research Site

    Debrecen, 4032, Hungary

  • Research Site

    Orosháza, 5900, Hungary

  • Research Site

    Pécs, 7624, Hungary

  • Research Site

    Chūōku, 103-0027, Japan

  • Research Site

    Itabashi-ku, 173-0004, Japan

  • Research Site

    Bratislava, 831 03, Slovakia

  • Research Site

    Brezno, 977 01, Slovakia

  • Research Site

    Lučenec, 984 01, Slovakia

  • Research Site

    Prešov, 080 01, Slovakia

  • Research Site

    Rožňava, 048 01, Slovakia

  • Research Site

    Svidník, 08901, Slovakia

  • Research Site

    Trebišov, 075 01, Slovakia

  • Research Site

    A Coruña, 15006, Spain

  • Research Site

    Barcelona, 08041, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Ferrol, 15405, Spain

  • Research Site

    Santiago(A Coruña), 15706, Spain

  • Research Site

    Seville, 41004, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Seville, 41071, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.